Polypeptide and antibody bound to polypeptide
An antibody for being specifically bound to a pro brain-derived neurotrophic factor (pro-BDNF) and a bound epitope. The antibody and the protein are used for treating autoimmune diseases. By inhibiting the activity induced by the pro-BDNF, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, lupus nephriti, chronic obstructive pulmonary diseases, asthma or cystic fibrosis, multiple sclerosis and other autoimmune diseases are treated.
1. An antibody or an antigen-binding fragment thereof that specifically binds to a precursor of brain-derived neurotrophic factor (pro-BDNF), wherein the antibody or antigen-binding fragment thereof comprises:
(a) a heavy chain variable region comprising a CDR1 as shown in SEQ ID NO: 1, a CDR2 as shown in SEQ ID NO: 2, and a CDR3 as shown in SEQ ID NO: 3, and a light chain variable region comprising a CDR1 as shown in SEQ ID NO: 4, a CDR2 as shown in SEQ ID NO: 5, and a CDR3 as shown in SEQ ID NO: 6; or
(b) a heavy chain variable region comprising a CDR1 as shown in SEQ ID NO: 11, a CDR2 as shown in SEQ ID NO: 12, and a CDR3 as shown in SEQ ID NO: 13, and a light chain variable region comprising a CDR1 as shown in SEQ ID NO: 14, a CDR2 as shown in SEQ ID NO: 15, and a CDR3 as shown in SEQ ID NO: 16.
2. An antibody or an antigen-binding fragment thereof that specifically binds to pro-BDNF, wherein the antibody or antigen-binding fragment thereof comprises:
(a) a heavy chain variable region as shown in SEQ ID NO: 7 and a light chain variable region as show in SEQ ID NO: 8;
(b) the amino acid sequence of SEQ ID NO: 21;
(c) a heavy chain variable region as shown in SEQ ID NO: 17 and a light chain variable region as shown in SEQ ID NO: 18; or
(d) the amino acid sequence of SEQ ID NO: 23.
3. The antibody of claim 1 , wherein the antibody is obtained by immunizing an animal or by screening a phage library using a polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 41.
4. A pharmaceutical composition comprising the antibody of claim 1 .
5. The pharmaceutical composition according to claim 4 , further comprising at least one pharmaceutically acceptable excipient, diluent, or a carrier.